ERBB2 and osteoporosis: Women who received AIs following a combination of chemotherapy and anti-HER2 therapy exhibited the highest risk of developing osteoporosis, followed by those receiving AIs (HR, 2.63; 95% CI, 2.41–2.86 and HR, 2.53; 95% CI, 2.37–2.7, respectively).